These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab. Mei MG; Cao TM; Chen L; Song JY; Siddiqi T; Cai JL; Farol LT; Al Malki MM; Salhotra A; Aldoss I; Palmer J; Herrera AF; Zain J; Popplewell LL; Chen RW; Rosen ST; Forman SJ; Kwak L; Nademanee AP; Budde LE Biol Blood Marrow Transplant; 2017 Nov; 23(11):1861-1869. PubMed ID: 28733266 [TBL] [Abstract][Full Text] [Related]
12. Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience. Bourcier J; Gastinne T; Leux C; Moreau A; Bossard C; Mahé B; Blin N; Dubruille V; Touzeau C; Voldoire M; Guillaume T; Peterlin P; Gallas P; Garnier A; Maisonneuve H; Moreau P; Juge-Morineau N; Jardel H; Chevallier P; Moreau P; Le Gouill S Ann Hematol; 2016 Aug; 95(8):1287-93. PubMed ID: 27297970 [TBL] [Abstract][Full Text] [Related]
13. Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. Chen RW; Palmer JM; Tomassetti S; Popplewell LL; Alluin J; Chomchan P; Nademanee AP; Siddiqi T; Tsai NC; Chen L; Zuo F; Abary R; Cai JL; Herrera AF; Rossi JJ; Rosen ST; Forman SJ; Kwak LW; Holmberg LA J Hematol Oncol; 2018 Jun; 11(1):87. PubMed ID: 29954415 [TBL] [Abstract][Full Text] [Related]
14. Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial. Ladetto M; Cortelazzo S; Ferrero S; Evangelista A; Mian M; Tavarozzi R; Zanni M; Cavallo F; Di Rocco A; Stefoni V; Pagani C; Re A; Chiappella A; Balzarotti M; Zilioli VR; Gomes da Silva M; Arcaini L; Molinari AL; Ballerini F; Ferreri AJM; Puccini B; Benedetti F; Stefani PM; Narni F; Casaroli I; Stelitano C; Ciccone G; Vitolo U; Martelli M Lancet Haematol; 2021 Jan; 8(1):e34-e44. PubMed ID: 33357480 [TBL] [Abstract][Full Text] [Related]
15. Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma. Sarkozy C; Callanan M; Thieblemont C; Obéric L; Burroni B; Bouabdallah K; Damaj G; Tessoulin B; Ribrag V; Houot R; Morschhauser F; Griolet S; Joubert C; Cacheux V; Delwail V; Safar V; Gressin R; Cheminant M; Delfau-Larue MH; Hermine O; Macintyre E; Le Gouill S Blood; 2024 Jul; 144(3):262-271. PubMed ID: 38669626 [TBL] [Abstract][Full Text] [Related]
16. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years. Kolstad A; Pedersen LB; Eskelund CW; Husby S; Grønbæk K; Jerkeman M; Laurell A; Räty R; Elonen E; Andersen NS; Brown PD; Kimby E; Bentzen H; Sundström C; Ehinger M; Karjalainen-Lindsberg ML; Delabie J; Ralfkiær E; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Kuittinen O; Niemann C; Geisler CH; Biol Blood Marrow Transplant; 2017 Mar; 23(3):428-435. PubMed ID: 28039078 [TBL] [Abstract][Full Text] [Related]
17. Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low-Tumor Burden Follicular Lymphoma. Kahl BS; Jegede OA; Peterson C; Swinnen LJ; Habermann TM; Schuster SJ; Weiss M; Fishkin PA; Fenske TS; Williams ME J Clin Oncol; 2024 Mar; 42(7):774-778. PubMed ID: 38194625 [No Abstract] [Full Text] [Related]
18. Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study. Houillier C; Dureau S; Taillandier L; Houot R; Chinot O; Moluçon-Chabrot C; Schmitt A; Gressin R; Choquet S; Damaj G; Peyrade F; Abraham J; Delwail V; Gyan E; Sanhes L; Cornillon J; Garidi R; Delmer A; Al Jijakli A; Morel P; Waultier A; Paillassa J; Chauchet A; Gastinne T; Laadhari M; Plissonnier AS; Feuvret L; Cassoux N; Touitou V; Ricard D; Hoang-Xuan K; Soussain C; J Clin Oncol; 2022 Nov; 40(32):3692-3698. PubMed ID: 35834762 [No Abstract] [Full Text] [Related]
19. Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma. Federico M; Fortpied C; Stepanishyna Y; Gotti M; van der Maazen R; Cristinelli C; Re A; Plattel W; Lazarovici J; Merli F; Specht L; Schiano de Colella JM; Hutchings M; Versari A; Edeline V; Stamatoulas A; Girinsky T; Ricardi U; Aleman B; Meulemans B; Tonino S; Raemaekers J; André M J Clin Oncol; 2024 Jan; 42(1):19-25. PubMed ID: 37967311 [No Abstract] [Full Text] [Related]
20. [Cytarabine and hematopoietic cell transplantation for mantle cell lymphoma. Analysis of 20 patients]. Campbell J; Hurtado S; Kutz C; Soto K; Ernst D Rev Med Chil; 2019; 147(1):9-17. PubMed ID: 30848759 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]